Zydus Lifesciences Limited (ZYDUSLIFE.NS)
- Previous Close
951.25 - Open
951.50 - Bid --
- Ask --
- Day's Range
944.50 - 958.65 - 52 Week Range
484.95 - 1,031.70 - Volume
697,527 - Avg. Volume
1,345,896 - Market Cap (intraday)
953.814B - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
32.47 - EPS (TTM)
29.18 - Earnings Date Apr 4, 2024
- Forward Dividend & Yield 6.00 (0.63%)
- Ex-Dividend Date Jul 28, 2023
- 1y Target Est
--
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India.
www.zyduslife.com23,026
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: ZYDUSLIFE.NS
Performance Overview: ZYDUSLIFE.NS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZYDUSLIFE.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZYDUSLIFE.NS
Valuation Measures
Market Cap
953.81B
Enterprise Value
935.55B
Trailing P/E
32.43
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.18
Price/Book (mrq)
5.09
Enterprise Value/Revenue
5.05
Enterprise Value/EBITDA
20.54
Financial Highlights
Profitability and Income Statement
Profit Margin
15.63%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
190.24B
Net Income Avi to Common (ttm)
29.56B
Diluted EPS (ttm)
29.18
Balance Sheet and Cash Flow
Total Cash (mrq)
15.19B
Total Debt/Equity (mrq)
0.92%
Levered Free Cash Flow (ttm)
--
Company Insights: ZYDUSLIFE.NS
ZYDUSLIFE.NS does not have Company Insights